NICE, the health technology appraisal body for England and Wales, has finally okayed Eisai Europe Ltd.'s breast cancer drug Halaven (eribulin), five years after it was first launched in the UK.
While the company will of course welcome the move, it says that in light of Halaven's long journey to routine...